<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207282</url>
  </required_header>
  <id_info>
    <org_study_id>CR108329</org_study_id>
    <secondary_id>54135419RSD4001</secondary_id>
    <nct_id>NCT03207282</nct_id>
  </id_info>
  <brief_title>Treatment Resistant Depression in America Latina</brief_title>
  <acronym>TRAL</acronym>
  <official_title>Treatment Resistant Depression in America Latina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the prevalence of Treatment Resistant Depression
      (TRD) among Major Depressive Disorder (MDD) participants being treated in a psychiatry
      reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American
      countries: Argentina, Brazil, Colombia and Mexico; and to evaluate all and depression-related
      healthcare resource utilization in TRD participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment Resistant Depression (TRD)</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <description>Prevalence of TRD will be assessed as percentage of participants with TRD among Major Depressive Disorder (MDD) participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Healthcare Resource Utilization in TRD Participants</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Healthcare resources utilized in TRD participants will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic Characteristics of TRD Participants</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <description>Demographic characteristics (such as age and gender) of TRD participants will be assessed at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Comorbid Conditions</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <description>Comorbid conditions of TRD participants will be assessed at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Patterns Over Time for TRD Participants</measure>
    <time_frame>Baseline (Day 1) up to Month 12</time_frame>
    <description>Treatment patterns of TRD participants will be assessed over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Duration for MDD</measure>
    <time_frame>Baseline (Day 1) up to Month 12</time_frame>
    <description>Treatment duration is defined as the time interval between baseline and time to next therapy (since the date of the first and second regimen to the start of third regimen).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Pattern for TRD Participants by Line</measure>
    <time_frame>Baseline (Day 1) up to Month 12</time_frame>
    <description>Treatment patterns for TRD participants will be determined by distribution of every line of the treatment regimen including pharmaceutical and non-pharmaceutical treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequence of Drugs</measure>
    <time_frame>Baseline (Day 1) up to Month 12</time_frame>
    <description>Sequence of drugs taken by TRD participants will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Symptoms as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Score</measure>
    <time_frame>Baseline (Day 1), Month 3, 6, 9 and 12</time_frame>
    <description>The MADRS is a 10 item scale for the evaluation of depressive symptoms (Montgomery et al 1979). The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. Each MADRS item is rated on a 0 to 6 scale with a total score ranging from 0 60. Higher MADRS scores indicate higher levels of depressive symptoms (more severe condition) and lower scores indicate a decreased severity of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Disability as Measured by Sheehan Disability Scale (SDS)</measure>
    <time_frame>Baseline (Day 1), Month 6, and 12</time_frame>
    <description>SDS is a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in the participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his or her (1) work, (2) social life or leisure activities, and (3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. To get a total score add up the 3 individual scores and the total score ranges from &quot;0 = unimpaired&quot; to &quot;30 = highly impaired&quot;. Higher scores indicate worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidality Risk (Ideation and Attempts) as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>Baseline (Day 1), Month 3, 6, 9, and 12</time_frame>
    <description>Suicidal ideation or behavior will be measured using C SSRS score. C-SSRS is a clinician rated assessment of suicidal behavior and/ or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 yes/no items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Costs in TRD Participants</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Total healthcare costs and healthcare costs related to depression will be determined in TRD participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect Cost Associated With Work Productivity Loss</measure>
    <time_frame>Baseline (Day 1) up to Month 12</time_frame>
    <description>Work productivity loss was measured by Work Productivity and Activity Impairment Questionnaire (WPAI). The WPAI is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on the job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect Cost Associated With Daily Functioning Loss</measure>
    <time_frame>Baseline (Day 1) up to Month 12</time_frame>
    <description>Indirect cost associated with daily functioning loss will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect Cost Associated With Caregiver Burden</measure>
    <time_frame>Baseline (Day 1) and Month 12</time_frame>
    <description>Indirect cost associated with caregiver burden will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect Cost Associated With Quality of Life</measure>
    <time_frame>Baseline (Day 1) and Month 12</time_frame>
    <description>Quality of life will be measured by EuroQol-5 Dimension (EQ-5D). The EQ-5D descriptive system comprises the following 5 dimensions: Mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 3 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health &quot;today.&quot; The descriptive system can be represented as a health state. The EQ-VAS self-rating records the respondent's own assessment of his or her overall health status, on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">387</enrollment>
  <condition>Depressive Disorder, Treatment-Resistant</condition>
  <arm_group>
    <arm_group_label>Participants with Diagnosis of Depression</arm_group_label>
    <description>Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consists of participants with Major Depressive Disorder (MDD) being
        treated in a psychiatry reference site (clinic, ambulatory, hospital, day-hospital) in 4
        Latin American countries and will be assessed to estimate the prevalence of Treatment
        Resistant Depression (TRD) among MDD participants.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase 1:

          -  Major depressive disorder (MDD) diagnosis according to the Diagnostic and Statistical
             Manual of Mental Disorders, 4th edition (DSM-IV), that was confirmed by MINI
             International Neuropsychiatric Interview, 5.0 version (MINI)

          -  Treated or untreated participants with a new or continued episode of depression at the
             time of the enrolment

          -  Participants must be capable of completing the corresponding assessments in the study

          -  Participants must be capable of signing the informed consent form

        Phase 2:

          -  Diagnosis of Treatment Resistant Depression (TRD), to be described by the
             investigator, based on the criteria:

               1. Adequate follow-up and treatment with at least 2 antidepressants

               2. Without complete response to treatment (based on Montgomery-Asberg Depression
                  Rating Scale [MADRS])

                  Exclusion Criteria:

          -  Participants diagnosed of psychosis, schizophrenia, bipolar disorder, schizoaffective
             disorder, or dementia

          -  Participants with substance dependence considered serious by the investigator

          -  Participant currently participating in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jannsen Cilag S.A. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Jannsen Cilag S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundación para el Estudio y Tratamiento de las Enfermedades Mentales</name>
      <address>
        <city>Ciudad Autonoma De Buenos Aires</city>
        <zip>C1425AHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CESASIN</name>
      <address>
        <city>Ciudad De Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto DAMIC</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Privada de Salud Mental Santa Teresa de Ávila</name>
      <address>
        <city>La Plata</city>
        <zip>B1904ADM</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>C.I.A.P. (Centro de investigación y Asistencia en Psiquiatría)</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Professor Edgar Santos</name>
      <address>
        <city>Bahia</city>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas Da Universidade Federal De Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>301301</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto De Neurociencias Dr. Quevedo Hospital Sao Sebastiao</name>
      <address>
        <city>Criciúma</city>
        <zip>88801-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial Tech Tecnologia em Pesquisas com Medicamentos</name>
      <address>
        <city>Curitiba</city>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidade Federal Do Ceara</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Bairral de Psiquiatria</name>
      <address>
        <city>Itapira</city>
        <zip>13970-905</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina da Universidade Federal de Pelotas</name>
      <address>
        <city>Pelotas</city>
        <zip>96030-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UFRJ - Instituto de Psiquiatria</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22210-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Psiquiatria - Hcfmusp</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Psiquiatria de Santa Catarina - IPqSC</name>
      <address>
        <city>São José</city>
        <zip>88123-300</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HOMO - ESE Hospital Mental de Antioquia</name>
      <address>
        <city>Bello, Antioquía</city>
        <zip>051053</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Colombiano del Sistema Nervioso</name>
      <address>
        <city>Bogota</city>
        <zip>110121</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.</name>
      <address>
        <city>Bogotá</city>
        <zip>111166</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Conciencia S.A.S</name>
      <address>
        <city>Medellín - Antioquia</city>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grupo de Estudios Médicos y familiares Carraci SC</name>
      <address>
        <city>Ciudad De Mexico</city>
        <zip>03740</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Estimulación Magnética Transcraneal de México S.C.</name>
      <address>
        <city>Ciudad De Mexico</city>
        <zip>11006</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Psiquiátrico Granja la Salud Tlazolteotl</name>
      <address>
        <city>Ixtapaluca</city>
        <zip>56530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Aranda de la Parra S.A. de C.V.</name>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Psiquiatrico Fray Bernardino Alvarez</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Psiquiatría 'Ramón de la Fuente Muñiz'</name>
      <address>
        <city>Mexico City</city>
        <zip>14370</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica de Neuropsiquiatría Tlatelolco ISSSTE</name>
      <address>
        <city>Mexico City</city>
        <zip>6900</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Neurología y Neurocirugía</name>
      <address>
        <city>Mexico</city>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Privarte Practice of Dr. Javier Zambrano</name>
      <address>
        <city>Mexico</city>
        <zip>15900</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Jalisciense de Salud Mental</name>
      <address>
        <city>Mexico</city>
        <zip>45170</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro para las Adicciones y Salud Mental S.A. de C.V.</name>
      <address>
        <city>Monterrey</city>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>cit NEUROPSIQUE</name>
      <address>
        <city>Monterrey</city>
        <zip>64610</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Central Dr Ignacio Morones Prieto</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica de Consulta Externa Alfredo del Mazo Vélez ISSEMyM</name>
      <address>
        <city>Toluca</city>
        <zip>50080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108329</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

